Speeding China’s innovation. Plus: 2026’s neuro catalysts — a BioCentury podcast

BioCentury This Week also features two neurology companies from the Emerging Company Profile series: U.S.-based Bexorg and French biotech Elkedonia

New rules in China will accelerate the country’s cell and gene therapy sector by reshaping how investigator-initiated trials are conducted and commercialized. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss the new framework and why it will create a powerful incentive for deploying new gene and cell therapies.

Executive Editor Selina Koch discusses which milestones she is watching in neurology in the year ahead, from psychedelics to Alzheimer's disease. Finally, Senior Biopharma Analyst Danielle Golovin discusses a pair of stories from BioCentury’s Emerging Company Profile series: one focused on Yale spinout Bexorg Inc., which is rethinking CNS drug discovery with a whole-human-brain model, and another on  Elkedonia S.A.S., a French start-up aiming at ELK1 to reboot neuroplasticity in depression.